NDA 021754 · Fujisawa Hlthcare
Mycamine
Micafungin Sodium · Injection
Last checked: Nov 20, 2026Latest source record: Mar 16, 2005 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Mar 16, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
58
16 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MYCAMINE · MICAFUNGIN SODIUM 50MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Micafungin" as an intervention, any sponsor and status, largest first.
- Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant PatientsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00001937 · 800 participants · Start Nov 1999
Drug: FK463; Fluconazole · For: Aspergillosis; Candidiasis; Fungemia and 1 more
Sites: Bethesda, Maryland
- Micafungin Versus AmBisome in Invasive Candidiasis and CandidemiaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00106288 · 637 participants · Start Jan 2003 · Primary completion Dec 2005
Drug: Micafungin; Liposomal Amphotericin B · For: Candidiasis
Sites: Birmingham, Alabama; Orange, California; Denver, Colorado · 37 sites in all
- Study of Micafungin in Patients With Invasive Candidiasis or CandidemiaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00105144 · 611 participants · Start Sep 2004 · Primary completion Apr 2006
Drug: Micafungin; Caspofungin · For: Candidiasis; Candidemia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 167 sites in all
- Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal CandidiasisPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00666185 · 523 participants · Start Aug 2003 · Primary completion Feb 2004
Drug: Micafungin; Fluconazole · For: Candidiasis, Oral
Sites: Abadia Uberaba, Brazil; Barretos, Brazil; Belo Horizonte, Brazil · 37 sites in all
- Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal CandidiasisPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00665639 · 454 participants · Start Jun 2004 · Primary completion Dec 2004
Drug: micafungin; caspofungin · For: Candidiasis, Oral
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Neuquén, Argentina · 31 sites in all
- Echinocandin Added to Standard Treatment for Severe Pneumocystis PneumoniaPivotal-lookingNot yet recruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT07900373 · 416 participants (planned) · Start Apr 1, 2027 · Primary completion Apr 1, 2032
Drug: Echinocandins; Placebo (0.9% Sodium chloride) infusion · For: Pneumocystis Jirovecii Pneumonia
Sites: Montreal, Canada
- Liver Transplant European Study Into the Prevention of Fungal InfectionPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01058174 · 350 participants · Start Dec 15, 2009 · Primary completion May 3, 2012
Drug: micafungin; fluconazole and 2 more · For: Liver Transplantation; Mycoses
Sites: Innsbruck, Austria; Antwerp, Belgium; Brussels, Belgium · 36 sites in all
Astellas Pharma IncAstellas (ALPMY)
NCT00036166 · 326 participants · Start Jan 29, 1999 · Primary completion Jan 31, 2002
Drug: FK463 · For: Aspergillosis
Sites: Graz, Austria; Linz, Austria; Créteil, France · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mycamine (Micafungin Sodium)
2024 spending
$101K
Beneficiaries
43
116 claims
Per beneficiary
$2,337
$55.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,161,578 |
| 2021 | $1,638,459 |
| 2022 | $616,055 |
| 2023 | $249,490 |
| 2024 | $100,505 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Echinocandin antifungal drugs.
Denning DW · Lancet 2003 · Clinical Trial, Comparative Study
- Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
Timsit JF, Azoulay E, Schwebel C, et al. · JAMA 2016 · Multicenter Study, Randomized Controlled Trial
- Echinocandin use in lung transplant recipients.
Al Jishi Y, Rotstein C, Kumar D, et al. · Clin Transplant 2018 · Clinical Trial
- The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: A systematic review.
Jendoubi A, Pressiat C, De Roux Q, et al. · Int J Antimicrob Agents 2024 · Systematic Review
- The impact of extracorporeal support on antimicrobial pharmacokinetics in critically ill neonatal and paediatric patients: A systematic review.
Cree ML, Abdul-Aziz MH, Schlapbach LJ, et al. · Int J Antimicrob Agents 2024 · Systematic Review
- [Candida glabrata : pathogenicity and therapy update].
Tietz HJ · Hautarzt 2012 · Clinical Trial
Sponsor: Fujisawa Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.